{"id":47620,"date":"2001-08-29T00:00:00","date_gmt":"2001-08-29T05:00:00","guid":{"rendered":"https:\/\/www.unmc.edu\/newsroom\/2001\/08\/29\/unmc-researchers-to-evaluate-potential-of-new-drugwith-standard-chemotherapy-for-stage-iii-ovarian-cancer\/"},"modified":"2022-08-29T10:51:34","modified_gmt":"2022-08-29T15:51:34","slug":"unmc-researchers-to-evaluate-potential-of-new-drugwith-standard-chemotherapy-for-stage-iii-ovarian-cancer","status":"publish","type":"post","link":"https:\/\/www.unmc.edu\/newsroom\/2001\/08\/29\/unmc-researchers-to-evaluate-potential-of-new-drugwith-standard-chemotherapy-for-stage-iii-ovarian-cancer\/","title":{"rendered":"UNMC Researchers to Evaluate Potential of New Drug\n\nwith Standard Chemotherapy for Stage III Ovarian Cancer"},"content":{"rendered":"

Researchers at the University of Nebraska Medical Center are participating<\/p>\n

in a nationwide clinical trial to evaluate the safety and effectiveness<\/p>\n

of combining standard initial chemotherapy with IM862, a compound that<\/p>\n

appears to have cancer fighting properties. Pre-clinical research suggests<\/p>\n

that IM862 stimulates the bodys immune system and inhibits the development<\/p>\n

of blood vessels needed by tumors to grow and spread.<\/p>\n

The University of Washington and Fred Hutchinson Cancer Research Centers<\/p>\n

Puget Sound Oncology Consortium will lead the multi-center trial which<\/p>\n

will involve 180 women with stage III ovarian cancer at 15 medical centers,<\/p>\n

in addition to Omaha. Study sites are also located in Seattle, St. Louis,<\/p>\n

Chapel Hill, N.C., Minneapolis, Los Angeles, Buffalo, N.Y., Madison, Wis.,<\/p>\n

Cleveland, Washington, D.C. and Palo Alto, Calif.<\/p>\n

About 27,000 new cases of ovarian cancer are detected each year in this<\/p>\n

country and some 15,000 women die annually from the disease. Because no<\/p>\n

reliable means of early detection exists, most cases are not diagnosed<\/p>\n

before they reach an advanced stage. The majority of women with stage III<\/p>\n

ovarian cancer initially achieve complete remission with surgery and standard<\/p>\n

chemotherapy. However, many patients relapse with time.<\/p>\n

It may provide more therapeutic benefits than other compounds. This<\/p>\n

is an exciting protocol because of its unique method of delivery, via nose<\/p>\n

drops, which patients can easily learn, said Kelly Molpus, M.D., director<\/p>\n

of the UNMC Division of Gynecologic Oncology. The side effects have been<\/p>\n

minimal, and therefore does not add significantly to the potential side<\/p>\n

effects of standard chemotherapy.<\/p>\n

To date, IM862 has been tested in clinical trials involving over 400<\/p>\n

cancer patients and has demonstrated a favorable safety profile with generally<\/p>\n

mild side effects, said Pamela Paley, M.D., gynecological oncologist at<\/p>\n

the University of Washington and one of the principal investigators of<\/p>\n

the study.<\/p>\n

IM862 may reduce blood vessels that feed tumor cells, as well as increase<\/p>\n

the ability of the patients own immune system to kill the cancer, said<\/p>\n

Dr. Paley. Our hope is that the combination of IM862 and chemotherapy<\/p>\n

will result in a larger number of women with ovarian cancer achieving long<\/p>\n

term remission from their disease with little or no additional toxicity.<\/p>\n

Women eligible for the study must be 18 years or older and newly diagnosed<\/p>\n

with stage III ovarian cancer and have undergone optimal surgery for removal<\/p>\n

of their tumor and not received prior treatment for their cancer. Patients<\/p>\n

will be randomized to one of three arms of the study, each with a different<\/p>\n

dose of IM862, while undergoing conventional treatment of six cycles of<\/p>\n

chemotherapy.<\/p>\n

Following combined treatment of chemotherapy and IM862, second look<\/p>\n

surgery will be performed to assess presence of disease. Patients with<\/p>\n

no evidence of disease, or with only microscopically detectable residual<\/p>\n

disease, will be treated with IM862 for an additional 24 weeks. The trial<\/p>\n

is double-blinded so neither patient nor physician will know which dose<\/p>\n

of study drug the patient is receiving.<\/p>\n

The studys primary objective is to determine the safety of IM862 when<\/p>\n

it is given with chemotherapy as well as if the addition of IM862 increases<\/p>\n

the percentage of patients with no evidence of disease at second look surgery.<\/p>\n

Historically, about half of patients show evidence of disease at that time.<\/p>\n

Secondary objectives include evaluation of occurrence of infection or other<\/p>\n

complications, length of remission and the ability of IM862 to decrease<\/p>\n

tumor blood supply and stimulate the immune system.<\/p>\n

IM862, developed by Cytran, Inc. of Kirkland, Wash., is a synthesized<\/p>\n

version of a naturally occurring small compound.<\/p>\n

For more information on the study, contact Dr. Molpus at (402) 559-5068<\/p>\n

or Cytran at (877) 449-4692 or visit the Cytran web site at www.cytran.com.<\/p>\no W S<\/a><\/div><\/div>","protected":false},"excerpt":{"rendered":"

Researchers at the University of Nebraska Medical Center are participating in a nationwide clinical trial to evaluate the safety and effectiveness of combining standard initial chemotherapy with IM862, a compound that appears to have cancer fighting properties. Pre-clinical research suggests that IM862 stimulates the bodys immune system and inhibits the development of blood vessels needed […]<\/p>\n","protected":false},"author":79,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-47620","post","type-post","status-publish","format-standard","hentry","category-uncategorized","department-press-release"],"yoast_head":"\nUNMC Researchers to Evaluate Potential of New Drug with Standard Chemotherapy for Stage III Ovarian Cancer<\/title>\n<meta name=\"description\" content=\"Researchers at the University of Nebraska Medical Center are participating in a nationwide clinical trial to evaluate the safety and effectiveness of\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.unmc.edu\/newsroom\/2001\/08\/29\/unmc-researchers-to-evaluate-potential-of-new-drugwith-standard-chemotherapy-for-stage-iii-ovarian-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UNMC Researchers to Evaluate Potential of New Drug with Standard Chemotherapy for Stage III Ovarian Cancer\" \/>\n<meta property=\"og:description\" content=\"Researchers at the University of Nebraska Medical Center are participating in a nationwide clinical trial to evaluate the safety and effectiveness of\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.unmc.edu\/newsroom\/2001\/08\/29\/unmc-researchers-to-evaluate-potential-of-new-drugwith-standard-chemotherapy-for-stage-iii-ovarian-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Newsroom\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/unmcedu\" \/>\n<meta property=\"article:published_time\" content=\"2001-08-29T05:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-08-29T15:51:34+00:00\" \/>\n<meta name=\"author\" content=\"UNMC Today\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@unmc\" \/>\n<meta name=\"twitter:site\" content=\"@unmc\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"UNMC Today\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/2001\\\/08\\\/29\\\/unmc-researchers-to-evaluate-potential-of-new-drugwith-standard-chemotherapy-for-stage-iii-ovarian-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/2001\\\/08\\\/29\\\/unmc-researchers-to-evaluate-potential-of-new-drugwith-standard-chemotherapy-for-stage-iii-ovarian-cancer\\\/\"},\"author\":{\"name\":\"UNMC Today\",\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/#\\\/schema\\\/person\\\/b7a10902696c45a5370b361e3a9ce621\"},\"headline\":\"UNMC Researchers to Evaluate Potential of New Drug with Standard Chemotherapy for Stage III Ovarian Cancer\",\"datePublished\":\"2001-08-29T05:00:00+00:00\",\"dateModified\":\"2022-08-29T15:51:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/2001\\\/08\\\/29\\\/unmc-researchers-to-evaluate-potential-of-new-drugwith-standard-chemotherapy-for-stage-iii-ovarian-cancer\\\/\"},\"wordCount\":622,\"publisher\":{\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/#organization\"},\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/2001\\\/08\\\/29\\\/unmc-researchers-to-evaluate-potential-of-new-drugwith-standard-chemotherapy-for-stage-iii-ovarian-cancer\\\/\",\"url\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/2001\\\/08\\\/29\\\/unmc-researchers-to-evaluate-potential-of-new-drugwith-standard-chemotherapy-for-stage-iii-ovarian-cancer\\\/\",\"name\":\"UNMC Researchers to Evaluate Potential of New Drug with Standard Chemotherapy for Stage III Ovarian Cancer\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/#website\"},\"datePublished\":\"2001-08-29T05:00:00+00:00\",\"dateModified\":\"2022-08-29T15:51:34+00:00\",\"description\":\"Researchers at the University of Nebraska Medical Center are participating in a nationwide clinical trial to evaluate the safety and effectiveness of\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/2001\\\/08\\\/29\\\/unmc-researchers-to-evaluate-potential-of-new-drugwith-standard-chemotherapy-for-stage-iii-ovarian-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/2001\\\/08\\\/29\\\/unmc-researchers-to-evaluate-potential-of-new-drugwith-standard-chemotherapy-for-stage-iii-ovarian-cancer\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/2001\\\/08\\\/29\\\/unmc-researchers-to-evaluate-potential-of-new-drugwith-standard-chemotherapy-for-stage-iii-ovarian-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"UNMC Researchers to Evaluate Potential of New Drug with Standard Chemotherapy for Stage III Ovarian Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/#website\",\"url\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/\",\"name\":\"Newsroom\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/#organization\",\"name\":\"University of Nebraska Medical Center\",\"url\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/overview-1.png\",\"contentUrl\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/overview-1.png\",\"width\":500,\"height\":153,\"caption\":\"University of Nebraska Medical Center\"},\"image\":{\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/unmcedu\",\"https:\\\/\\\/x.com\\\/unmc\",\"https:\\\/\\\/instagram.com\\\/iamunmc\",\"https:\\\/\\\/www.youtube.com\\\/user\\\/UNMCEDU\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/#\\\/schema\\\/person\\\/b7a10902696c45a5370b361e3a9ce621\",\"name\":\"UNMC Today\",\"sameAs\":[\"https:\\\/\\\/www.unmc.edu\\\/strategic-communications\"],\"url\":\"https:\\\/\\\/www.unmc.edu\\\/newsroom\\\/author\\\/d1fe173d08e959397adf34b1d77e88d7\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"UNMC Researchers to Evaluate Potential of New Drug with Standard Chemotherapy for Stage III Ovarian Cancer","description":"Researchers at the University of Nebraska Medical Center are participating in a nationwide clinical trial to evaluate the safety and effectiveness of","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.unmc.edu\/newsroom\/2001\/08\/29\/unmc-researchers-to-evaluate-potential-of-new-drugwith-standard-chemotherapy-for-stage-iii-ovarian-cancer\/","og_locale":"en_US","og_type":"article","og_title":"UNMC Researchers to Evaluate Potential of New Drug with Standard Chemotherapy for Stage III Ovarian Cancer","og_description":"Researchers at the University of Nebraska Medical Center are participating in a nationwide clinical trial to evaluate the safety and effectiveness of","og_url":"https:\/\/www.unmc.edu\/newsroom\/2001\/08\/29\/unmc-researchers-to-evaluate-potential-of-new-drugwith-standard-chemotherapy-for-stage-iii-ovarian-cancer\/","og_site_name":"Newsroom","article_publisher":"https:\/\/www.facebook.com\/unmcedu","article_published_time":"2001-08-29T05:00:00+00:00","article_modified_time":"2022-08-29T15:51:34+00:00","author":"UNMC Today","twitter_card":"summary_large_image","twitter_creator":"@unmc","twitter_site":"@unmc","twitter_misc":{"Written by":"UNMC Today","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.unmc.edu\/newsroom\/2001\/08\/29\/unmc-researchers-to-evaluate-potential-of-new-drugwith-standard-chemotherapy-for-stage-iii-ovarian-cancer\/#article","isPartOf":{"@id":"https:\/\/www.unmc.edu\/newsroom\/2001\/08\/29\/unmc-researchers-to-evaluate-potential-of-new-drugwith-standard-chemotherapy-for-stage-iii-ovarian-cancer\/"},"author":{"name":"UNMC Today","@id":"https:\/\/www.unmc.edu\/newsroom\/#\/schema\/person\/b7a10902696c45a5370b361e3a9ce621"},"headline":"UNMC Researchers to Evaluate Potential of New Drug with Standard Chemotherapy for Stage III Ovarian Cancer","datePublished":"2001-08-29T05:00:00+00:00","dateModified":"2022-08-29T15:51:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.unmc.edu\/newsroom\/2001\/08\/29\/unmc-researchers-to-evaluate-potential-of-new-drugwith-standard-chemotherapy-for-stage-iii-ovarian-cancer\/"},"wordCount":622,"publisher":{"@id":"https:\/\/www.unmc.edu\/newsroom\/#organization"},"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.unmc.edu\/newsroom\/2001\/08\/29\/unmc-researchers-to-evaluate-potential-of-new-drugwith-standard-chemotherapy-for-stage-iii-ovarian-cancer\/","url":"https:\/\/www.unmc.edu\/newsroom\/2001\/08\/29\/unmc-researchers-to-evaluate-potential-of-new-drugwith-standard-chemotherapy-for-stage-iii-ovarian-cancer\/","name":"UNMC Researchers to Evaluate Potential of New Drug with Standard Chemotherapy for Stage III Ovarian Cancer","isPartOf":{"@id":"https:\/\/www.unmc.edu\/newsroom\/#website"},"datePublished":"2001-08-29T05:00:00+00:00","dateModified":"2022-08-29T15:51:34+00:00","description":"Researchers at the University of Nebraska Medical Center are participating in a nationwide clinical trial to evaluate the safety and effectiveness of","breadcrumb":{"@id":"https:\/\/www.unmc.edu\/newsroom\/2001\/08\/29\/unmc-researchers-to-evaluate-potential-of-new-drugwith-standard-chemotherapy-for-stage-iii-ovarian-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.unmc.edu\/newsroom\/2001\/08\/29\/unmc-researchers-to-evaluate-potential-of-new-drugwith-standard-chemotherapy-for-stage-iii-ovarian-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.unmc.edu\/newsroom\/2001\/08\/29\/unmc-researchers-to-evaluate-potential-of-new-drugwith-standard-chemotherapy-for-stage-iii-ovarian-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.unmc.edu\/newsroom\/"},{"@type":"ListItem","position":2,"name":"UNMC Researchers to Evaluate Potential of New Drug with Standard Chemotherapy for Stage III Ovarian Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.unmc.edu\/newsroom\/#website","url":"https:\/\/www.unmc.edu\/newsroom\/","name":"Newsroom","description":"","publisher":{"@id":"https:\/\/www.unmc.edu\/newsroom\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.unmc.edu\/newsroom\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.unmc.edu\/newsroom\/#organization","name":"University of Nebraska Medical Center","url":"https:\/\/www.unmc.edu\/newsroom\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.unmc.edu\/newsroom\/#\/schema\/logo\/image\/","url":"https:\/\/www.unmc.edu\/newsroom\/wp-content\/uploads\/2022\/08\/overview-1.png","contentUrl":"https:\/\/www.unmc.edu\/newsroom\/wp-content\/uploads\/2022\/08\/overview-1.png","width":500,"height":153,"caption":"University of Nebraska Medical Center"},"image":{"@id":"https:\/\/www.unmc.edu\/newsroom\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/unmcedu","https:\/\/x.com\/unmc","https:\/\/instagram.com\/iamunmc","https:\/\/www.youtube.com\/user\/UNMCEDU"]},{"@type":"Person","@id":"https:\/\/www.unmc.edu\/newsroom\/#\/schema\/person\/b7a10902696c45a5370b361e3a9ce621","name":"UNMC Today","sameAs":["https:\/\/www.unmc.edu\/strategic-communications"],"url":"https:\/\/www.unmc.edu\/newsroom\/author\/d1fe173d08e959397adf34b1d77e88d7\/"}]}},"_links":{"self":[{"href":"https:\/\/www.unmc.edu\/newsroom\/wp-json\/wp\/v2\/posts\/47620","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.unmc.edu\/newsroom\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.unmc.edu\/newsroom\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/newsroom\/wp-json\/wp\/v2\/users\/79"}],"replies":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/newsroom\/wp-json\/wp\/v2\/comments?post=47620"}],"version-history":[{"count":1,"href":"https:\/\/www.unmc.edu\/newsroom\/wp-json\/wp\/v2\/posts\/47620\/revisions"}],"predecessor-version":[{"id":74217,"href":"https:\/\/www.unmc.edu\/newsroom\/wp-json\/wp\/v2\/posts\/47620\/revisions\/74217"}],"wp:attachment":[{"href":"https:\/\/www.unmc.edu\/newsroom\/wp-json\/wp\/v2\/media?parent=47620"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.unmc.edu\/newsroom\/wp-json\/wp\/v2\/categories?post=47620"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.unmc.edu\/newsroom\/wp-json\/wp\/v2\/tags?post=47620"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}